| Chairman |
|
Lu Qiang |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman: Lu Qiang Chief Executive Officer & General Manager: Lan Jiong Executive Director: Zhang Wei Non-executive Director: Zhu Jingyang(formerly known as Zhu Daqiang), Tao Sha Independent Non-executive Director: Lu-Wong Shaohua Christine, Zhou Demin, Li Bo.
|
| Principle Business |
|
The Group is principally engaged in biopharmaceutical business, primarily focused on developing therapies for oncology, as well as autoimmune and inflammatory diseases. |
| Major Shareholders |
| Lu Qiang & ASSO | 67,560,720 | H Sh | - | 19.98% | 2025/10/21 | | HL Partners II L.P. | 22,418,890 | H Sh | 6.28% | 6.91% | 2025/09/19 |
|
|
|
|